Company to hold conference call and webcast on Monday, September 12th at 4:30 PM Eastern Standard Time (EST) VANCOUVER, BC & SEATTLE, WA — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical… Read More
Phase 1b Results Demonstrate Encouraging Median Progression-Free Survival of 5.7 Months in Difficult-to-Treat Patient Population THOUSAND OAKS, CA — Amgen (NASDAQ: AMGN) today announced updated data from its Phase 1b CodeBreaK 101 study,… Read More
Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repair Lukashev brings over 20 years’ experience including work at Biogen and the ALS Therapy Development Institute… Read More
VANCOUVER, BC — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received… Read More
This fall, UVic Biomedical Engineering, in partnership with UVic’s Gustavson School of Business and UBC’s School of Biomedical Engineering, is pleased to offer a micro-credential on Project Management for Biomedical… Read More
